Considered along with patient studies that show IL11 to be highly upregulated in the colonic mucosa of patients with ulcerative colitis or Crohn’s disease and that IL11 predicts treatment failure [32–34], our results highlight IL11 as a promising therapeutic target for IBD, particularly in the context of anti-TNF therapy resistance. Here, IL11 is linked to inflammatory bowel disease.